Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice

Circulation

Volumn 113, Issue 1, 2006, Pages 108-117

  Babaev, Vladimir R ^a,b   Ding, Lei ^a   Reese, Jeff ^a   Morrow, Jason D ^b   Breyer, Matthew D ^a   Dey, Sudhansu K ^a   Fazio, Sergio ^a,b   Linton, MacRae F ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclooxygenase; Macrophages; Platelets; Prostaglandins; Thromboxane

Indexed keywords

APOLIPOPROTEIN E; CALCIMYCIN; CHOLESTEROL; CYCLOOXYGENASE 1; GLYCOPROTEIN IIB; LIPOPOLYSACCHARIDE; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROSTAGLANDIN DERIVATIVE; PROTEIN; THROMBOXANE; TO 901317; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; THROMBOXANE A2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL TRANSPLANTATION; CELL TYPE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENZYME DEFICIENCY; LIVER CELL; MOUSE; NONHUMAN; NULL ALLELE; PATHOGENESIS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; THROMBOCYTE COUNT; THROMBOSIS; ANIMAL; BIOSYNTHESIS; BONE MARROW CELL; ENZYMOLOGY; GENETICS; MOUSE MUTANT; PHYSIOLOGY; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CYCLOOXYGENASE 1; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, LDL; THROMBOXANE A2; UP-REGULATION;

EID: 33644858279     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.591537     Document Type: Article

References (38)

1. DuBois R, Abramson S, Crofford L, Gupta RA, Simon L, Van De Putte L, Lipsky P. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073.
2. Vane JR, Bakhle YS, Botting RM. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
3. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, Yacoub MH, Polak JM. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999;19:646-655.
4. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999;155:1281-1291.
5. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2:879-890.
6. Bailey JM, Butler J. Anti-inflammatory drugs in experimental atherosclerosis, I: relative potencies for inhibiting plaque formation. Atherosclerosis. 1973;17:515-522.
7. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816-1823.
8. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A. 2001;98:3358-3363.
9. Belton OA, Duffy A, Toomey S, Fitzgerald DJ. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation. 2003;108:3017-3023.
10. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163:2006-2010.
11. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997;96:2751-2753.
12. Wu KK. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003;3:107-112.
13. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539-541.
14. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest. 2004;114:784-794.
15. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:1724-1728.
16. Egan KM, Wang M, Lucitt MB, Zukas AM, Pure E, Lawson JA, FitzGerald GA. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation. 2005;111:334-342.
17. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995;83:483-492.
18. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apoE deficient mice by bone marrow transplantation. Science. 1995;267:1034-1037.
19. Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, Gleaves LA, Atkinson JB, Linton MF. Increased atherosclerosis in C57BL/6 mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci U S A. 1997;94:4647-4652.
20. Marnett LJ, Wright TL, Crews BC, Tannenbaum SR, Morrow JD. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem. 2000;275:13427-13430.
21. Babaev VR, Patel MB, Semenkovich CF, Fazio S, Linton MF. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J Biol Chem. 2000;275:26293-26299.
22. Paigen B, Holmes P, Mitchell D, Albee D. Comparison of atherosclerotic lesions and HDL-lipid levels in male, females, and testosterone-treated female mice from strains C57BL/6, BALB/c and C3H. Atherosclerosis. 1987;68:215-221.
23. Nieswandt B, Echtenacher B, Wachs FP, Schroder J, Gessner JE, Schmidt RE, Grau GE, Mannel DN. Acute systemic reaction and lung alterations induced by an antiplatelet integrin GP IIb/IIIa antibody in mice. Blood. 1999;94:684-693.
24. Rocca B, Spain LM, Pure E, Langenbach R, Patrono C, FitzGerald GA. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest. 1999;103:1469-1477.
25. Zhang J, Goorha S, Raghow R, Ballou LR. The tissue-specific, compensatory expression of cyclooxygenase-1 and -2 in transgenic mice. Prostaglandins Other Lipid Mediat. 2002;67:121-135.
26. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003;9:213-219.
27. de Leval X, Hanson J, David JL, Masereel B, Pirotte B, Dogne JM. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Med Chem. 2004;11:1243-1252.
28. Reese J, Paria B, Brown N, Zhao X, Morrow J, Dey S. Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse. Proc Natl Acad Sci U S A. 2000;97:9759-9764.
29. Babaev VR, Fazio S, Gleaves LA, Carter KJ, Semenkovich CF, Linton MF. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J Clin Invest. 1999;103:1697-1705.
30. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1709-1711.
31. Hermann M, Krum H, Ruschitzka F. To the heart of the matter: coxibs, smoking, and cardiovascular risk. Circulation. 2005;112:941-945.
32. McAdam BF, Byrne D, Morrow JD, Oates JA. Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation. 2005;112:1024-1029.
33. Senna SM, Moraes RB, Bravo MF, Oliveira RR, Miotto GC, Vidor AC, Bello-Klein A, Irigoyen MC, Bello AA, Curi R, Homem de Bittencourt PI Jr. Effects of prostaglandins and nitric oxide on rat macrophage lipid metabolism in culture: implications for arterial wall-leukocyte interplay in atherosclerosis. Biochem Mol Biol Int. 1998;46:1007-1018.
34. Nishimura T, Yamamoto T, Ueda Y, Yamada K, Kara Y. Stable prostaglandin I1 analog SM-10906 modulates productions of tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in mouse macrophages. Biol Pharm Bull. 2000;23:708-711.
35. Raychaudhuri B, Malur A, Bonfield TL, Abraham S, Schilz RJ, Farver CF, Kavuru MS, Arroliga AC, Thomassen MJ. The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages. J Biol Chem. 2002;277:33344-33348.
36. Huebner SB, Babaev VR, Zhang Y, Fazio S, Linton MF. Bone marrow stem cells are a source of smooth muscle and endothelial cells in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2003;23:84a. Abstract.
37. Reese J, Brown N, Paria BC, Morrow J, Dey SK. COX-2 compensation in the uterus of COX-1 deficient mice during the preimplantation period. Mol Cell Endocrinol. 1999;150:23-31.
38. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol. 2005;39:443-452.